



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 18TH SEPTEMBER
2019 AT 12.30pm

IN SEMINAR ROOM 4, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
-------------	----------------------------------------

2019/119: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Mr A Gray (AG)	Clinical Pharmacist, ELHT

2019/120: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2019/121: MINUTES OF AUGUST MEETING:

Item 2019/110: TA583 – Traffic light should be Green

Item 2019/111: TA5890 – should be TA589

Accepted as a correct record when amendments done.

2019/122: MATTERS ARISING:

2019/064: Formulary Updates - Tranexamic acid injection for topical use – SJ has had a response from the tissue viability nurses. Hospice pharmacist is working with Palliative care team and will have some guidance for next meeting.

2019/095: New Product Request – Parathyroid hormone (Natpar®) – sent to LMMG and it has been included on their workplan.

2019/098: LMMG Recommendations (From June LMMG)

Insulin Toujeo Information Sheet – updated – ELHE one page version with all main points presented. Accepted for use in ELHE. To be uploaded to website and circulated as a Hot Topic.

Guidelines for the Prescribing of Nutritional Supplements Post Bariatric Surgery – LR to feed comments from last meeting to LMMG. Local guideline on hold.

Riluzole Shared Care Guideline - LR to feed comments from last meeting to LMMG.

2019/099: LMMG Recommendations (From July LMMG)

Testosterone Shared Care Guideline - LR to feed comments from last meeting to LMMG

Deferred Items:

2019/105: NHSE LOW PRIORITY PRESCRIBING COMMISSIONING GUIDANCE

The guidance for CCGs has been updated in June with seven new items and one updated item. ELHE formulary is already aligned with the majority of these additions and work is ongoing with needles for insulin pens. Updated guidance to be uploaded to website

Resolved: Items which should not routinely be prescribed in primary care. Guidance for CCGs June 2019 to be uploaded to website.

2019/106: HOSPITAL ADMISSIONS CHECKLIST - UPDATED

The checklist for transfer of medicines between care homes and hospital has been updated to include additional medication. An omission highlighted was medicines used for Parkinson's Disease. There were some concerns raised that care home staff may not be able to identify which medicines are in the groups listed. LR agreed to share with CCG Care Home Team for comments.

Action: LR to share with CCG Care Home Team and provide feedback.

2019/108: NHSE STANDARD GMS CONTRACT 2019 – EXCESSIVE PRESCRIBING

Section 14.9 from NHSE standard GMS contract states the following with respect to excessive prescribing:

'14.9.1. The Contractor must not prescribe drugs, medicines or appliances the cost or quantity of which, in relation to a patient, is, by reason of the character of the drug, medicine or appliance in question, in excess of that which was reasonably necessary for the proper treatment of the patient.

14.9.2. In considering whether a Contractor has breached its obligations under 14.9.1, the Board must seek the views of the Local Medical Committee (if any) for the area in which the Contractor provides services under the Contract.'

It was agreed to include this reference on ELMMB website.

Resolved: Section 14.9 of NHSE Standard GMS contract 2019 to be included on website.

2019/109: LANCASHIRE CARE SUBCUTANEOUS SYRINGE PUMP PROTOCOL - UPDATE

The protocol has been updated with the EL anticipatory medicines guidance. The document is due for full review in December.

Updated protocol acknowledged and to be uploaded to website.

Resolved: Updated protocol acknowledged.

2019/123: NEW PRODUCT REQUEST – HYDROCORTISONE SODIUM PHOSPHATE INJECTION

Application withdrawn.

2019/124: NEW PRODUCT REQUEST – TIMOLOL TOPICAL AND PROPRANOLOL ORAL FOR INFANTILE HAEMANGIOMAS

Timolol topical and oral propranolol, requested by paediatrics team, for treatment of infantile haemangiomas that require treatment (many do not require treatment). There is limited evidence for timolol topical and that is only for small superficial haemangiomas. It was agreed that timolol topical would not be included on formulary. There is evidence for the use of oral propranolol for those haemangiomas with a potential to impair function or cause permanent disfigurement. It was agreed that oral propranolol would be included on the formulary for treatment of infantile haemangiomas with amber traffic light.

Resolved: Propranolol oral included on formulary for treatment of infantile haemangiomas.

Traffic light: AMBER

Timolol topical not to be included on formulary.

2019/125: NEW PRODUCT REQUEST – FARCO-FILL[®] PROTECT

Farco-fill[®] Protect solution is requested by the continence team for use with indwelling catheters. It was not clear from the application if this was a trial and who was supporting it. It was agreed to ask a representative to attend the next ELMMB to discuss the request.

Action: Invite representative of continence team to discuss at next ELMMB.

2019/126: LMMG CONSULTATIONS (for Oct LMMG)

Cariprazine New Medicine Assessment – Antipsychotic recommended by LMMG as amber when there are predominately negative symptoms. Evidence is quite weak but there are few options for negative symptoms. An amber traffic light would be supported if there was a clear pathway for where it fit in treatment and if a shared care was developed.

Insulin Glargine/ Lixisenatide (Suliqua[®]) New Medicines Assessment – black traffic light supported by ELMMB.

Resolved: Comments to be sent to LMMG

2019/127: LMMG Recommendations (From Aug LMMG)

No LMMG meeting in August.

2019/128: FORMULARY UPDATES

Enoxaparin – for Acute Coronary Syndrome – as second line option for patients with eGFR < 20mL/min as fondaparinux is contraindicated in this group of patients. Agreed to include this indication for enoxaparin.

Aminophylline tablets – requested to be included on formulary as an option for dosing and many patients already taking. CCG's to look at use in primary care and the associated costs. Bring data back to next meeting.

Capsacain cream – currently both strengths are unavailable. Check NICE recommendations and bring back to next meeting

Resolved: Formulary to be updated as above

2019/129: SPS GUIDE: DOAC DOSING IN RENAL IMPAIRMENT

The SPS dosing guide for DOACs in renal impairment has been updated to use actual body weight for most drugs. Acknowledged and to be uploaded to website.

Resolved: Updated DOAC dosing in Renal Impairment SPS guide acknowledged.

2019/130: CCG NON-MEDICAL PRESCRIBING POLICY

Updated in light of new NHSE information. Acknowledged and to be uploaded to website

Resolved: CCG Non-medical Prescribing Policy acknowledged.

2019/131: TREATMENT OF VITAMIN B12 DEFICIENCY DRAFT

A proposed draft guideline on the treatment of vitamin B12 deficiency has been developed in response to requests from GPs. This has been shared with colleagues from ELHT for comment. CD had received some correspondence which she agreed to forward. Once the information from all stakeholders has been collated, it was agreed to bring proposal back to ELMMB.

Action: CD to forward copy of email referring to cyanocobalamin. JV/LR to consult with key stakeholders and bring back revised guideline.

2019/132: NICE RECOMMENDATIONS (from Aug)

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma [TA592] is recommended as an option by NICE. Approved in line with NICE. Cancer Drugs Fund **Traffic Light: RED**

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer [TA593] is recommended as an option by NICE. Approved in line with NICE. Cancer Drugs Fund **Traffic Light: RED**

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594) **Traffic Light: BLACK**

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595) is recommended as an option by NICE. Approved in line with NICE. NHS England Commissioned **Traffic Light: RED**

Dapagliflozin with insulin for treating type 1 diabetes (TA597) is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned **Traffic Light: AMBER**

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598) is recommended as an option by NICE. Approved in line with NICE. Cancer Drugs Fund **Traffic Light: RED**

2019/133: NICE HIGHLY SPECIALISED TECHNOLOGY (HST) GUIDANCE

Patisiran for treating hereditary transthyretin amyloidosis. (HST10) – August 2019

STANDING ITEMS

2019/134: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – June 2019

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 16th October 2019 12.30pm, Seminar Room 6, Learning & Development Centre, RBH.

Please note meetings have reverted back to 12.30pm – 2pm

Dates for 2019: All 3rd Wednesday of the month starting at 12.30pm

16th October

20th November

18th December

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 18Th SEPTEMBER 2019

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/064	Formulary Updates – Tranexamic acid – guidance from palliative care team to come to next meeting	CW	Oct 19
2019/098	LMMG Recommendations (From June LMMG) Guidelines for the Prescribing of Nutritional Supplements Post Bariatric Surgery – comments to LMMG and local guideline to be reviewed Riluzole Shared Care Guideline – request LMMG to review febrile illness wording	LR JV LR	Sept 19 Sept 19 Sept 19
2019/099	LMMG Recommendations (From July LMMG) Testosterone Shared Care Guideline – request LMMG add ‘fasting’ to the blood sample information	LR	Sept 19
2019/106	Hospital Admissions Checklist – Updated – share with CCG Care Home Team and provide feedback.	LR	Oct 19
2019/125	New Product Request – Farco-Fill[®] Protect – invite representative of continence team to next ELMMB	CW	Oct 19
2019/128	Formulary Updates – Aminophylline tablets – primary care use and costs Capsacin cream – check NICE guidance recommendation	LR/JV LR/JV	Oct 19 Oct 19
2019/131	Treatment Of Vitamin B12 Deficiency Draft – email received by GP practices to be forwarded Consult with stakeholders and bring back revised guideline	CD LR/JV	Oct 19 Nov 19